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Abstract
Background—Fecal incontinence (FI) is a prevalent but poorly recognized problem in the 
general population with profound negative effects on daily life. The prevalence of FI in IBS and its 
association with clinical, demographic and pathophysiological factors are largely unknown.
Methods—One US (n=304) and one Swedish (n=168) patient cohort fulfilling Rome III criteria 
for IBS completed Rome III diagnostic questions on FI and IBS symptoms, and questionnaires on 
IBS symptom severity, quality of life, anxiety and depression, and work productivity impairment. 
The patients also underwent assessments of colorectal sensitivity and motility.
Key Results—FI ≥ one day per month was reported by 19.7% (USA) and 13.7% (Sweden) of 
IBS patients. These proportions rose to 43.4% and 29.8% if patients with less frequent FI were 
included. FI prevalence was higher in older age groups, with a clear increase above age 40. IBS 
patients with FI reported greater overall IBS symptom severity, more frequent and loose stools, 
and greater urgency. Negative effects of FI on quality of life, psychological distress, and work 
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productivity were demonstrated. No associations were found between colorectal physiology and 
FI.
Conclusions & Inferences—FI is common in IBS patients, and similar to previous general 
population reports, the major risk factors for FI in IBS are older age, rectal urgency, and loose, 
frequent stools. When IBS patients have comorbid FI, the impact on quality of life, psychological 
symptoms, and work impairment appears greater.
Keywords
Irritable bowel syndrome; fecal incontinence; functional GI disorders
Introduction
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal 
disorders (FGIDs) with a pooled world-wide prevalence of 11% in existing studies 1, but 
with large differences in prevalence figures due to methodological variance and 
heterogeneity between studies 2. IBS is defined by the Rome III criteria and is characterized 
by a combination of abdominal pain or discomfort and abnormal bowel habits 3. Apart from 
the characteristic IBS symptoms included in the diagnostic criteria, many patients with IBS 
also suffer from other troublesome symptoms and syndromes, including other FGIDs, non-
gastrointestinal symptoms and psychiatric comorbid disorders 4-6. Among FGIDs, especially 
the overlap with functional dyspepsia is well documented 7-9, whereas the overlap with other 
conditions with disturbed gastrointestinal (GI) function is less well studied. Despite being a 
benign condition from a medical point of view, quality of life is substantially reduced in IBS 
patients 10, 11, and comorbid GI and non-GI conditions adds further to the disease burden 
and quality of life impairment 12.
Fecal incontinence, defined as unintentional loss of solid or liquid stool 13, is a common but 
often neglected problem in the population. Prevalence estimates for community-dwelling 
subjects range from 7 to 15%, with discrepancies between studies partly being explained by 
differences in survey methods, age range of included subjects, and definitions of fecal 
incontinence 13. In several studies increasing age, burden of general illness, rectal urgency 
and diarrhea have been identified as risk factors for fecal incontinence 14-17. When fecal 
incontinence is frequent or associated with larger amounts of stool loss, it can have a 
profound negative impact on quality of life 18-20, and often leads to embarrassment, 
isolation, reduced scope of life activities such as travel or social events, and psychological 
distress. Moreover, only a minority of individuals with fecal incontinence discuss this 
problem with their physician, leaving the problem unaddressed and untreated for many of 
those who suffer substantial adverse consequences 21-23.
In population-based studies IBS has been found to be a risk factor for fecal 
incontinence 14, 15. However, despite the fact that these two prevalent conditions constitute a 
substantial burden of the workload for gastroenterologists and GI surgeons, and lead to high 
costs for society 1, 2, 13, 24, 25, surprisingly few studies have assessed the overlap between 
IBS and fecal incontinence. Moreover, factors associated with coexistence of the conditions 
and their combined additive effect on the overall disease burden are incompletely 
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understood. In the existing studies that have evaluated the prevalence of fecal incontinence 
in patients with IBS, the rates differ substantially, ranging from 6.2% to 57% 21, 26, 27. These 
seemingly discrepant results are likely in part attributable to differences in patient selection, 
definition of fecal incontinence and screening questions. These studies have also yielded 
mixed results regarding the association between fecal incontinence in IBS, IBS symptom 
severity, demographic factors, health care seeking, psychological factors, bowel habits and 
quality of life 21, 26, 27. Moreover, none of these studies have evaluated the association with 
key pathophysiological factors in IBS, such as visceral hypersensitivity and GI motor 
abnormalities 28-32.
Therefore, in this study we used two large, well-characterized cohorts of IBS patients from 
two western countries with different healthcare systems but comparable prevalence of IBS 
and fecal incontinence 1, 2, 17, 33, 34 to estimate and compare: 1) the prevalence of fecal 
incontinence in IBS; 2) the impact of fecal incontinence on quality of life and other 
measures of disease burden; and 3) demographic, clinical, and physiological predictors of 
fecal incontinence.
Materials and Methods
Subjects
We included subjects with IBS according to the Rome III criteria 3, who participated in two 
prospective studies assessing the relevance of pathophysiological factors for symptoms in 
IBS 28, 35-38. The patients in the first of these study cohorts were recruited from the 
outpatient clinic specialized in functional GI disorders at Sahlgrenska University Hospital in 
Gothenburg, Sweden. The majority of them were referred to the unit by their general 
practitioner or through self-referral. The diagnosis was based on a typical clinical 
presentation and additional investigations if considered necessary by the gastroenterologist 
(HT or MS), but most patients had already undergone sufficient examinations by the 
referring physician, and all patients met the Rome III criteria for IBS. IBS patients between 
18 and 65 years were included. Exclusion criteria were: other GI disease(s) explaining the 
patient's symptoms; other severe disease(s) such as malignancy, severe heart disease, kidney 
disease, or neurological disease; symptoms indicating other severe disease(s) such as GI 
bleeding, weight loss or fever; severe psychiatric disease; a history of drug or alcohol abuse 
within 6 months prior to enrollment; or pregnancy at the time of the study.
The second cohort was patients in a research clinic specialized in functional GI disorders at 
the University of North Carolina in Chapel Hill, USA. The patients were 18 years or older 
(no upper limit), and were recruited by advertisements or physician referrals and screened by 
telephone before inclusion. They met the Rome III criteria for IBS, and had been diagnosed 
with IBS by a physician before enrollment, which was confirmed by means of an interview 
and examination conducted by a gastroenterologist. Exclusion criteria were: other GI 
disease(s) explaining the patient's symptoms, including GI resection (other than 
appendectomy or cholecystectomy), known inflammatory bowel disease, coeliac disease, 
lactose malabsorption; heart disease; diabetes mellitus; or pregnancy at the time of the study.
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All patients in both study cohorts were given study-specific verbal and written information 
before giving their written consent to participate in the studies. The Regional Ethical Review 
Board in Gothenburg, and the Institutional Review Board of the University of North 
Carolina, respectively, approved the study prior to the start of patient enrollment.
Study Measures
Questionnaires
Demographics: Basic demographic information about participants was obtained by a study 
nurse / research coordinator at both sites, using a standardized case report forms. Of these 
variables, age, gender, height and weight (for calculation of body mass index) were used in 
the analyses in this study.
GI symptoms: The severity of IBS symptoms was evaluated at both sites with the widely 
used and validated questionnaire, IBS Severity Scoring System (IBS-SSS) 39. This 
questionnaire is based on five items; frequency and severity of abdominal pain, severity of 
abdominal distension, bowel habit dissatisfaction and interference of IBS with daily life. The 
questionnaire uses visual analogue scales and each item is scored 0-100, which yields a total 
score ranging from 0 to 500, with higher scores reflecting more severe symptoms. 
According to validated cut-off levels, the patients were divided into IBS severity groups of 
mild IBS (score of <175), moderate IBS (175-300), or severe IBS (>300). The patients also 
completed the Rome III diagnostic questionnaire for the adult functional GI disorders 40. For 
this study, we included select questions from this questionnaire with three purposes: 1) 
Questions in the IBS module to verify that the patients fulfilled the Rome III criteria for IBS; 
2) Questions to characterize the presence and type of fecal incontinence / accidental bowel 
leakage in the last three months: frequency (never – less than one day a month – one day a 
month – two to three days a month – one day a week – more than one day a week – every 
day), amount (small - moderate - large), and composition of leakage (liquid/mucus only – 
stool only – both liquid/mucus and stool); and 3) Questions to characterize the bowel habit 
of the patient: frequent (≥ 4 / day) or infrequent (<3 / week) bowel movements, hard or 
lumpy stools, loose or watery stools and urgency (have to rush to the toilet to have a bowel 
movement) (response alternatives for all these questions: never or rarely – sometimes – often 
– most of the time – always). The information about the frequency of hard and lumpy stools, 
and loose and watery stools was also used for subgrouping of the IBS patients with the 
response of “sometimes” being used as the cut-off level (this is the appropriate equivalent of 
25% of the time according to the Rome III committee) 3, 40.
Disease-specific quality of life: Different validated disease-specific quality of life 
instruments were used in the two cohorts. In the Swedish study, the Hahn et al Irritable 
Bowel Syndrome Quality of Life Questionnaire (IBSQOL) was used 41. This 30-item 
questionnaire measures nine quality of life domains found to be of relevance for IBS: 
emotional health, mental health, sleep, energy, physical functioning, food/diet, social 
functioning, physical role and sexual relations. Each scale score is transformed to a scale of 
0-100, with 100 representing the best possible quality of life. In the US cohort, the Patrick 
and Drossman Irritable Bowel Syndrome Quality of Life scale (IBS-QOL) was used 42. This 
is a 34-item questionnaire that measures the impact of IBS on quality of life in eight 
Simrén et al. Page 4
Neurogastroenterol Motil. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
domains; dysphoria, interference with activity, body image , health worry, food avoidance , 
social reaction, sexual, and relationships. The scores are transformed to a 0-100 scale, where 
100 represents the best possible quality of life.
Psychological distress: Different validated questionnaires were also used to assess 
psychological distress by measuring the severity of anxiety and depression in the two 
countries. In the Swedish cohort, the widely used Hospital Anxiety and Depression scale 
(HADS) was used. This is a mood scale developed for use in non-psychiatric clinical 
settings to identify patients with psychological distress. It consists of 14 items, evenly 
divided into two subscales, one for anxiety and one for depression. It uses a 4-point Likert 
scale (0-3), which provides a minimum score of 0 (no symptoms) and a maximum score of 
21 (maximal severity of symptoms) on each subscale. In the US sample the anxiety and 
depression subscales of the Brief Symptom Inventory-18 (BSI-18) were used 43. Each of 
these subscales consist of six items asking how much the patients were bothered by each of 
the symptoms, on a 0-4 scale ranging from “not bothered at all” to “extremely bothered”. 
The sum scores of the subscales were transformed to standardized scores, where the mean 
for the healthy population is 50 and each standard deviation is 10 (T scores). The 
standardized scores also adjust for sex differences.
Work productivity and Activity: This was only measured in the Swedish sample by using 
the Work Productivity and Activity Index – irritable bowel syndrome version 
(WPAI:IBS) 44. This questionnaire consists of six questions, and from these four metrics can 
be derived: absenteeism (the percentage of work time missed due to IBS in the past 7 days), 
presenteeism (the percentage of impairment suffered while at work due to IBS in the past 7 
days), overall work impairment (the total percentage of missed time due to IBS-related 
absenteeism or presenteeism in the past 7 days), and activity impairment (the percentage of 
impairment suffered due to IBS during daily activities in the past 7 days). Each metric varies 
from 0 to 100%, with higher scores indicating greater impairment.
Physiologic measures
Colorectal sensitivity: Balloon distensions using an electronic barostat (Dual Drive 
Barostat, Distender Series II; G&J Electronics INC, Toronto, Ontario, Canada) were 
performed at both sites to assess colorectal sensitivity. The Swedish patients underwent a 
rectal barostat study using an ascending methods of limits ramp distension protocol starting 
at 0 mmHg and increasing in steps of 4mmHg every minute up to the pain threshold or to a 
maximum balloon pressure of 60 mmHg. Thresholds for first sensation, urgency, discomfort 
and pain were assessed 45. In the US patients, a colonic barostat test (where the test balloon 
was placed in the sigmoid colon with fluoroscopy guidance) was performed in the earliest of 
the consecutive patients (n=68), whereas the remainder underwent a rectal barostat study 28. 
Both tests used an ascending methods of limits paradigm with phasic distensions of 30 sec 
duration separated by 30 sec rest intervals with the balloon at the operating pressure (i.e., the 
minimum pressure needed for inflating the balloon). The distensions started 2 mmHg above 
the operating pressure and increased progressively in 2 mmHg steps until the subject 
reported pain of moderate intensity (3 on a 0-4 scale) or until a balloon pressure of 48 
mmHg was reached. Thresholds for defecatory urge and pain were determined. To be able to 
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combine the thresholds from the colonic and rectal barostat studies in the US sample, Z-
scores (defining how many standard deviations a value is from the mean) were calculated. 
For the analyses in this study only the urge and pain thresholds from both the Swedish and 
US cohorts were used. Furthermore, as a measure of smooth muscle tone in the US cohort, 
average balloon volume at the operating pressure was analyzed (Z-scores)28, and in the 
Swedish cohort the balloon pressure at half of the maximum observed volume (P1/2) was 
used as a measure of compliance45.
Colorectal motility: The Swedish patients underwent a colonic transit time measurement by 
ingesting 10 radiopaque markers per day during six consecutive days, and on the morning of 
the seventh day the remaining markers were counted using fluoroscopy (Exposcop 7000 
Compact; Ziemh GmbH; Nüremberg, Germany) 30. The colonic transit time in days was 
obtained by dividing the number of retained markers with the daily dose, i.e. 10. In the US 
IBS cohort colorectal motility was studied as part of colon and rectal barostat protocols. A 
water-perfused manometry catheter (Model C7-CB-00256, Mui Scientific, Ontario, Canada) 
and a physiologic recorder (Sandhill Scientific, Highlands Ranch, Colorado, USA) was used 
to record phasic motility 2.5 and 5 cm both proximal and distal to the balloon during 10 min 
balloon distension at 20 mmHg above the operating pressure, and for 30 min following an 
810 kcal meal 28. A motility index averaging the phasic contractility during the distension 
and after the meal, respectively, was calculated using dedicated software (Polygram, Lower 
GI Edition, Version 5.06; Synectics Medical, now Medtronic Inc., Minneapolis, MN).
Data analysis—Statistical analyses were performed with the software package IBM SPSS 
Statistics version 22 (IBM Corporation, Armonk, NY). Data are presented as mean ± SD and 
proportions (%). As a first step we analyzed the proportion of IBS subjects who reported 
accidental bowel leakage with different frequencies, the amount leaked and the composition 
of the bowel leakage. Thereafter, we compared IBS patients with fecal incontinence 
(accidental bowel leakage ≥ one day per month) 17 to IBS patients without fecal 
incontinence (accidental bowel leakage never or < one day/month). Chi-squared test was 
used to analyze the association of fecal incontinence to categorical data: gender, age groups 
(≤30, 31-40, 41-50, >50 years); IBS subgroup; and bowel habits (Rome III questionnaire – 
categories based on frequencies and binned into three groups: never or rarely; sometimes or 
often; most of the time or always). Continuous data from questionnaires and physiological 
tests were analyzed with Student's t-test. In case of borderline significance, further 
exploratory analyses were performed using other cut-offs to define fecal incontinence. In 
order to determine factors independently associated with fecal incontinence (“risk factors”), 
we performed binary logistic regression analyses in the two cohorts with fecal incontinence 
(accidental bowel leakage ≥ one day per month) as the dependent variable, and factors 
univariately associated with fecal incontinence as independent variables. Statistical 
significance was accepted at p<0.05.
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Results
Subjects
We included 168 IBS patients fulfilling the Rome III criteria 3 in the Swedish cohort and 304 
Rome III positive IBS patients in the US cohort. Demographic and disease related 
information for the two cohorts is displayed in table 1. As can be seen, the gender 
distribution and the mean age were comparable between cohorts, but the age range was 
wider in the US cohort as only subjects aged 18-65 years were included in the Swedish 
cohort. The patients in the Swedish cohort had more severe IBS symptoms and slightly 
lower BMI than the US patients, but the distribution of IBS subtypes based on the Rome III 
diagnostic questionnaire was similar in both cohorts with a clear predominance of patients 
with IBS-M. In the Swedish cohort all patients were Caucasian, whereas the US cohort was 
68.5% Caucasian, 28.1% African American, 1.3% Asian, and 2.0% American Indian / 
Alaska natives.
Fecal incontinence in IBS
As can be seen in Figure 1, accidental bowel leakage ≥ one day a month was reported by 
19.7% of IBS patients in the US and 13.7% in Sweden. These proportions rose to 43.4% in 
the US and 29.8% in Sweden if patients with bowel leakage less than one day a month in the 
last three months were included. The majority of the subjects with accidental bowel leakage 
reported leaking only small amounts (staining only) (US 79%; Sweden 86%), whereas 19% 
in the US and 12% in Sweden reported moderate amounts of leaking (more than staining but 
less than a full bowel movement). In both cohorts only 2% of subjects reporting accidental 
bowel leakage lost large amounts, i.e. a full bowel movement. Among those with any bowel 
leakage, the composition of the leakage was described as liquid/mucus only by 47% in the 
US and 30% in Sweden, as stool only by 18% in the US and 24% in Sweden, and as both 
liquid/mucus and stool by 35% in the US and 46% in Sweden. For further analyses fecal 
incontinence was defined as accidental bowel leakage ≥ one day a month 17, unless stated 
otherwise.
Fecal incontinence and demographics in IBS
The mean age was higher in US IBS patients with fecal incontinence than in patients without 
fecal incontinence (44.7±13.0 vs. 34.1±12.7 years; p>0.0001), with a non-significant 
tendency in the same direction in the Swedish cohort (37.0±12.2 vs 33.2±11.2 years; p=0.1). 
However, when comparing Swedish IBS patients who reported accidental bowel leakage 
ever (including “less than one day a month”) with patients who never reported leakage, 
patients with leakage were older than those without leakage (38.0±12.4 vs. 32.0±10.6 years; 
p<0.002). Dividing the patients into age groups demonstrated a clear increase in prevalence 
of fecal incontinence above age 40 in both the US (p<0.0001) and Sweden (p<0.05) (Figure 
2), and again the differences were more prominent in the Swedish sample if a less restrictive 
cut-off for defining fecal incontinence (ever vs. never accidental bowel leakage) was used 
(ever FI prevalence: <30 years: 20.0%; 31-40 years: 28.2 %; 41-50 years 57.7%; >50 years: 
38.9%; p=0.002). Fecal incontinence with moderate or large amounts of leakage rarely 
occurred below age 40 (Figure 2). There were no gender differences in fecal incontinence 
prevalence in the US (19% of females vs. 21% of males; p=0.69) or Swedish IBS patients 
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(13% of females vs. 16% of males; p=0.69). In the US patients body mass index was higher 
in IBS patients with fecal incontinence compared to those without fecal incontinence 
(28.4±6.8 vs. 26.4±5.9 kg/m2; p=0.03), but this was not the case in the Swedish cohort 
(24.5±2.9 vs. 23.4±4.2 kg/m2; p=0.22). In the US cohort fecal incontinence was equally 
common in Caucasian (42/165; 20.3%) and African American (17/68; 20.0%) IBS patients.
Fecal incontinence and other GI symptoms in IBS
IBS patients with fecal incontinence reported greater overall IBS symptom severity on the 
IBS-SSS in both the US (293±90 vs 265±88; p=0.03) and Swedish (348±86 vs. 290±90; 
p=0.02) cohorts. Assessment of bowel habit characteristics (Figure 3) showed that in both 
cohorts, fecal incontinence was significantly associated with heightened frequency of 
diarrhea-type symptoms: having more than 4 bowel movements per day (US: p<0.0001; 
Sweden: p=0.04), loose/watery stools (US: p<0.0001; Sweden: p=0.002), and urgency (US: 
p<0.0001; Sweden: p=0.005). Conversely, a tendency was seen only in US patients for IBS 
patients with fecal incontinence to have less frequent constipation-type symptoms: less than 
3 bowel movements / week (US: p=0.07; Sweden: p=0.86) and hard/lumpy stools (US 
p=0.03; Sweden: p=0.76). Fecal incontinence was numerically most common in patients 
with IBS-D subtype, but this reached significance only in the US cohort (US: IBS-D: 31.4%; 
IBS-M 19.7%; IBS-C: 5.8%; p=0.002; Sweden: IBS-D: 17.5%; IBS-M: 13.5%; IBS-C 
5.9%; p=0.5).
Fecal incontinence and psychological distress, quality of life and work productivity in IBS
In the Swedish cohort, IBS patients with fecal incontinence had more anxiety (11.3±4.9 vs. 
7.9±4.2; p=0.001) and depression (7.7±3.9 vs. 4.9±3.4; p<0.0001) on the HADS compared 
to patients without fecal incontinence, but this was not seen in the US cohort (BSI-18 
anxiety: 50.9±9.9 vs. 51.9±10.4; p=0.5; BSI-18 depression: 51.8±10.9 vs. 52.6±10.8; 
p=0.6). Disease specific quality of life was lower for seven of ten quality of life domains on 
the IBSQOL in Swedish IBS patients with fecal incontinence, and for interference with 
activities and body image domains on the IBS-QOL in US IBS patients, as can be seen in 
Figure 4. In the Swedish cohort work productivity and activity measures of the WPAI:IBS 
showed greater impairment in patients with fecal incontinence (Figure 5); this information 
was not available in the US cohort.
Fecal incontinence and colorectal physiology in IBS
- In both cohorts patients underwent barostat tests to evaluate colorectal sensitivity 
(Table 2). There were no differences in urge or pain thresholds between patients with 
vs. without fecal incontinence in either sample. In the US cohort we also measured 
colorectal phasic motility response to stimuli and found no differences between 
patients with and without fecal incontinence. Moreover, smooth muscle tone (US 
cohort) and compliance (Swedish patients) were similar in both patient groups (Table 
2). Colonic transit time was measured in the Swedish IBS patients and it did not 
differ between patients with and without fecal incontinence.
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Factors independently associated with fecal incontinence
Factors univariately associated with reporting fecal incontinence (accidental bowel leakage ≥ 
one day a month) were thereafter entered into binary logistic regression models in the two 
cohorts (US cohort: age; body mass index; IBS severity (IBS-SSS); frequent stools, loose 
stools and urgency (Rome III questionnaire). Swedish cohort: age; IBS severity (IBS-SSS); 
frequent stools, loose stools and urgency (Rome III questionnaire); anxiety and depression 
(HAD). In the US cohort urgency (β=1.80 (95% CI 1.14-2.83), p=0.01) and age (β=1.06 
(95% CI 1.04-1.09) were found to be independently associated with fecal incontinence 
(Nagelkerke R2=0.30), whereas only urgency (β=1.99 (95% CI 1.14-2.83), p<0.05) made a 
unique statistically significant contribution to the model in Swedish IBS patients 
(Nagelkerke R2=0.32).
Discussion
In this study we have demonstrated that a substantial proportion, 14-20%, of Swedish and 
US IBS patients, who predominantly seek health care for their IBS symptoms, also suffer 
from fecal incontinence, which appears higher than the rates typically reported in general 
population samples 17, 33, 34. Moreover, we found that fecal incontinence adds to the burden 
of IBS, with significant adverse impact seen on quality of life, psychological symptoms, and 
work productivity. The risk factors for fecal incontinence in both US and Swedish patients 
with IBS were similar to those reported for the general population 14-17.
One of the problems when comparing fecal incontinence prevalence between studies is the 
use of different definitions and different questionnaires. In our study, both cohorts used the 
same questionnaire, Rome III diagnostic questionnaire for the adult functional GI 
disorders 40, and fecal incontinence was defined as accidental bowel leakage at least once 
per month, a definition that has been used in a recent US national survey 17 and also fits with 
the current definition of FGIDs 3, 40, 46, 47. The prevalence of fecal incontinence using this 
definition differed between the cohorts, with a somewhat higher prevalence in US patients 
with IBS. This is hard to explain with the existing data, but a wider age range in the US 
cohort with more older subjects may be one explanation. Even though prevalence of fecal 
incontinence was associated with IBS symptom severity, differences in prevalence rates 
between the cohorts cannot be explained by more severe IBS symptoms in the US cohort 
because the pattern was the opposite. Differences in health care systems, health care seeking 
behavior and willingness to participate in studies may have influenced our results, since our 
data are not population-based, but rather collected from IBS patients who were willing to 
participate in research studies on IBS pathophysiology. When our prevalence rates are 
compared with relevant studies of general population samples with of equivalent age, the 
prevalence of fecal incontinence appears higher than can be expected for a random 
population sample. In the US sample, the 19.7% rate of fecal incontinence in our IBS 
patients was more than double the 8.3% rate reported in a nation-wide U.S. population 
survey of 4,308 individuals that used the same definition of fecal incontinence, i.e. 
accidental bowel leakage at least one day a month 17. Although, slightly different definitions 
and questions were used in a Swedish population-based survey, the fecal incontinence rates 
in the Swedish IBS patients in the present study also appear higher than in the general 
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population 34. From a clinical point of view it seems highly relevant that one in every five to 
six IBS patients accidentally leaks stool each month, and if a less strict definition is used 
(also including accidental bowel leakage less than one day a month in the last three months), 
three to four out of every ten patients have fecal incontinence. Based on the authors’ 
experiences, these high prevalence rates are likely unknown to many clinicians managing 
IBS patients.
The few existing studies that have addressed the prevalence of fecal incontinence in IBS 
have reported broadly varied prevalence rates 21, 26, 27. In our study we found that 14-20% of 
our IBS patients reported accidental bowel leakage at least one day a month in the last three 
months. This seems very different from the prevalence rate of fecal incontinence of 57% in a 
large clinical IBS sample in the study by Atarodi and colleagues 21. However, in that study 
patients with accidental bowel leakage less than once a year were included in their definition 
of fecal incontinence, and 24% of those had mild (“once a year or less”), 35% had moderate 
(“once a month or less but more than once a year”) , and 32% had severe fecal incontinence 
(“once a week or more or nocturnal”). Therefore, these findings are actually not so different 
from the findings in the present study, where we used a more stringent minimal frequency 
definition for identifying fecal incontinence cases (i.e., at least once in the last month). The 
other two studies that have addressed the overlap between IBS and fecal incontinence found 
that 18-23% of patients with IBS in a health maintenance organization (HMO) 27, and 
6-20% of subjects with “bowel dysfunction compatible with IBS” in a survey of students 
reported that they “ever lost control of their bowels (including soiling of underwear)” 26. 
These studies are also difficult to compare directly with our findings, as the age range of 
subjects, the study settings, and incontinence definitions are very different
Perhaps of even greater importance than the prevalence rates per se, is the finding that 
coexistence of IBS and fecal incontinence negatively influence quality of life, and work 
productivity and activity, i.e. the presence of fecal incontinence seem to potentiate the 
already substantial disease burden in IBS. Work productivity and activity is reduced in IBS 
patients 48, 49, which leads to high costs for society 50 and reduced quality of life for 
patients 48. In our Swedish sample we used the validated WPAI:IBS questionnaire to assess 
work productivity and activity 44 and could demonstrate increased impairment in all four 
outcome measures with this questionnaire (absenteeism, presenteeism, overall work 
impairment and activity impairment) in patients who had both IBS and fecal incontinence. 
Moreover, although there is no mortality or medically severe complications associated with 
IBS, the quality of life in IBS patients is reduced to the same extent as in many other chronic 
conditions associated with severe morbidity and mortality 10. In both our IBS cohorts, the 
presence of fecal incontinence was associated with even greater impairment in quality of 
life, and in the US cohort this impairment was associated with quantity of incontinence – 
i.e., leaking moderate to large amounts of fecal material. These findings are in agreement 
with a study on patients with fecal incontinence where the presence of IBS was found to 
substantially impair quality of life 51, and also consistent with several other studies 
demonstrating that fecal incontinence is associated with reduced quality of life 18, 19. 
Regarding the association with psychological symptoms, there were differences between our 
cohorts. In the Swedish cohort, patients with fecal incontinence and IBS had more severe 
psychological distress than patients with IBS only, but this was not seen in the US cohort. 
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Unfortunately, different questionnaires to assess psychological distress were used in the two 
studies, so direct comparisons are not possible, but factors related to the questionnaires per 
se, may explain differences between the cohorts. Taken together, the findings on quality of 
life, work productivity and psychological distress in our cohorts clearly demonstrates the 
additive burden fecal incontinence poses for patients with IBS, and highlights the 
importance of addressing and managing this symptom adequately in IBS patients in order to 
improve quality of life, psychological well-being, and work productivity.
In population-based studies several risk factors, or factors associated with fecal incontinence 
have been identified. Bowel habit disturbances, particularly diarrhea, rectal urgency, 
increasing age, being overweight, decreased physical activity, obstetrical injury, and poor 
general health are all factors that have been found to be associated with the presence and 
severity of fecal incontinence in several studies 14, 15, 17, 52. In our study we could confirm 
that several of these factors also seem to be associated with fecal incontinence in IBS. Loose 
and frequent stools, as well as urgency were clearly associated with fecal incontinence in 
both cohorts. Increasing age was also associated with fecal incontinence, with a clear 
increase in the prevalence above age 40, and moderate or large amount of leakage starting to 
appear above that age. Based on these data, it clearly seems as if having IBS is a risk factor 
for developing fecal incontinence when you grow older. In the Swedish cohort a seemingly 
paradoxical decrease in the proportion of subjects with fecal incontinence was seen in the 
group of patients > 50 years of age (Figure 2), which can be explained by the small number 
of subjects in this group (n=18), as well as by a smaller proportion of patients in this age 
group reporting diarrhea predominance (2/18 patients) compared with the other age groups 
(p<0.05). Moreover, the oldest patient in the Swedish cohort was 60 years compared with 73 
years in the US cohort, which may be one explanation for the stronger association between 
age and fecal incontinence in US patients. Less consistent results were seen for body mass 
index, with an association with fecal incontinence only in the US sample. No gender 
differences in fecal incontinence prevalence were noted, which is consistent with previous 
population based studies 17, 49. Moreover, we could not detect an association with colorectal 
sensorimotor function in either of the two cohort.
There are obvious strengths with our studies, such as large patient cohorts, largely similar 
findings from studying patients in two different countries with different healthcare systems, 
careful and comprehensive phenotypic characterization with widely used and validated 
questionnaires, and uniform methodology. However, there are also important limitations. 
The patients were seen at secondary / tertiary care centers, so the findings cannot be 
generalized to IBS patients in primary care. Moreover, the patients were primarily included 
because of their IBS symptoms, which may have led to an underestimation of the true 
prevalence and severity of fecal incontinence in patients with IBS, since IBS patients with 
more dominant and severe fecal incontinence may not volunteer for studies where the main 
focus lies on IBS symptoms and the underlying pathophysiology. Furthermore, our failure to 
see physiological differences between IBS patients with fecal incontinence compared to 
those without may be a consequence of the fact that we did not assess anal function with 
anorectal manometry, and we do not have information about obstetrical injuries. Moreover, 
as the IBS patients were from two different countries with different health care systems and 
social conventions, it is possible that cultural taboos about discussing toileting behavior and 
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incontinence may differ between the countries and influence our prevalence estimates for 
fecal incontinence. However, there are no major differences in prevalence rates in 
population-based studies on fecal incontinence between Sweden and the US 1, 2, 17, 33, 34. 
Therefore, we see the inclusion of two cohorts from different countries as a strength and an 
opportunity to test the replicability of the results across two large samples. The fact that 
there were many similarities between the findings in the two cohorts supports the 
generalizability of our findings in IBS – at least in regard to secondary or tertiary care 
patients.
To conclude, we have demonstrated that fecal incontinence is present in a sizeable 
proportion of patients who primarily seek health care for IBS in Sweden and the US. The 
major risk factors for fecal incontinence seem to be similar in IBS and in the general 
population: older age, rectal urgency, and loose, frequent stools. When IBS patients have 
comorbid fecal incontinence, the impact on quality of life, psychological symptoms, and 
work impairment appears greater than in IBS alone. Therefore, including questions about 
fecal incontinence when taking clinical history in IBS may guide management and improve 
clinical outcomes. Future studies should determine the underlying physiologic abnormalities 
for fecal incontinence in IBS through careful anorectal function assessment, and ideally be 
population-based.
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Key Points
• Fecal incontinence is prevalent in the general population and has profound 
negative effects on daily life. Few studies have assessed the overlap between 
IBS and fecal incontinence.
• Fecal incontinence was reported by 14 to 20% of IBS patients, and it was 
associated with loose, frequent stools, urgency, and adverse impact on quality 
of life, psychological symptoms, and work productivity.
• Clinicians managing patients with IBS should include questions about fecal 
incontinence when taking the clinical history since this may guide 
management and improve clinical outcomes.
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Figure 1. 
Response to the question: “In the last three months, how often have you accidently leaked 
liquid or solid stool?” in the US and Swedish IBS cohorts.
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Figure 2. 
Association between fecal incontinence, including the amount of leakage, and age groups in 
US (A) and Swedish (B) IBS patients.
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Figure 3. 
Association between the presence of fecal incontinence (FI) and frequency of bowel habit 
characteristics in US (A) and Swedish (B) IBS patients. The bars show the proportion of 
subjects reporting a specific frequency of a bowel habit characteristics who also report fecal 
incontinence (accidental bowel leakage at least one day a month).
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Figure 4. 
Disease-specific quality of life in patients with or without fecal incontinence (FI) in the US 
cohort (A) and in the Swedish cohort (B). * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001.
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Figure 5. 
Work productivity and activity measured with WPAI:IBS in Swedish IBS patients with or 
without fecal incontinence (FI). * p<0.05; ** p<0.01;
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Table 1
Demographic and disease related information.
US Cohort (n=304) Swedish cohort (n=168)
Gender (Female/Male, %) 77% / 23% 70% / 30%
Age (mean±SD, range) 36±14 (18-73) 34±11 (18-60)
Body Mass Index (kg/m2) 26.8±6.1 23.5±4.0
IBS-SSS (mean±SD) 271±89 304±91
IBS severity (IBS-SSS; %)
    Mild 12.0% 6.8%
    Moderate 48.7% 39.8%
    Severe 39.3% 53.4%
IBS Subtype (Rome III; %)
    IBS-C 17.3% 10.1%
    IBS-D 23.3% 23.8%
    IBS-M 59.3% 66.1%
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Table 2
Colorectal physiologic measures
US Cohort FI (n=60) No FI (n=244) p value
Colorectal urge threshold (Z-score) 0.02±1.2 −0.03±1.0 0.9
Colorectal pain threshold (Z-score) −0.11±1.1 −0.04±1.0 0.7
Smooth muscle tone (Z-score) −0.12±0.9 −0.02±0.9 0.5
Motility index, distention 964±960 961±574 0.9
Motility index, post-meal 692±465 594±501 0.2
Swedish cohort FI (n=23) No FI (n=145) p-value
Rectal urge threshold (mmHg) 18.5±7.2 19.5±7.0 0.5
Rectal pain threshold (mmHg) 26.7±10.2 27.2±8.6 0.8
Compliance (P1/2) (mmHg) 16.1±6.0 15.3±5.5 0.5
Colonic transit time (days) 1.4±1.1 1.5±1.0 0.7
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